Impax Asset Management Group plc Purchases 32,833 Shares of Zoetis Inc. (NYSE:ZTS)

Impax Asset Management Group plc increased its position in Zoetis Inc. (NYSE:ZTS) by 48.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 100,615 shares of the company’s stock after buying an additional 32,833 shares during the period. Impax Asset Management Group plc’s holdings in Zoetis were worth $16,393,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. AMF Tjanstepension AB lifted its stake in shares of Zoetis by 23.4% in the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after purchasing an additional 20,001 shares during the last quarter. Howard Capital Management Group LLC raised its holdings in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after buying an additional 883 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Zoetis by 28.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 61,653 shares of the company’s stock worth $12,011,000 after buying an additional 13,699 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Zoetis by 2.5% during the 3rd quarter. Arkadios Wealth Advisors now owns 5,045 shares of the company’s stock worth $986,000 after acquiring an additional 121 shares in the last quarter. Finally, Modera Wealth Management LLC increased its holdings in shares of Zoetis by 20.6% during the 3rd quarter. Modera Wealth Management LLC now owns 26,424 shares of the company’s stock valued at $5,163,000 after acquiring an additional 4,517 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $165.51 on Tuesday. The firm’s 50-day moving average is $166.30 and its 200-day moving average is $177.78. The company has a market cap of $74.12 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s payout ratio is 36.56%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZTS shares. Piper Sandler reduced their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $215.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.